Discontinuation of chronic renal dialysis following treatment with autologous bone marrow derived multi-potent mesenchymal stromal cells targeted with low energy acoustic shockwaves; the first successful case report

Abstract

Bone marrow derived autologous mesenchymal stromal stem cells (MSCs) represent an important potential source of multi-potent cells that can induce anti-inflammatory effects and be differentiated into cells resembling many other tissues. As such, treatment using MSCs represents a potential future approach for repair of disease-associated tissue damage and possibly also age-dependent wear & tear. Considering the successful and safe use of MSCs for treatment of many different clinical conditions caused by inflammatory or immune mediated tissue damage on the one hand, and for cosmetic and orthopedic indications for repair of cartilage and bone defects and for successful treatment of neurologic diseases caused by neuroinflammatory or neurodegenerative disorders, on the other, supported by pre-clinical experiments in mice and rats confirming the potential therapeutic effects of MSCs for treatment of experimental kidney damage and successful prior clinical investigations confirming that treatment with MSCs is safe, we have decided to pioneer the use of multi-potent MSCs for repair of renal failure in a patient that could no longer tolerate the use of hemodialysis. This case report represents the first successful clinical experience of an elderly patient with end-stage renal disease dependent on hemodialysis x3/week for 2 years that responded to treatment with autologous bone marrow derived MSCs in parallel with treatment with low energy acoustic shockwave therapy and remained off dialysis for 6 years.